<DOC>
	<DOCNO>NCT01482871</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy ophthalmic intravitreal injection ALG - 1001 human subject diabetic macular edema . The primary endpoint study observation dose limit toxicity maximum tolerate dose . The secondary endpoint study observation clinical effect BCVA ( ETDRS letter ) OCT central macular thickness .</brief_summary>
	<brief_title>Safety Study ALG- 1001 Treat Diabetic Macular Edema</brief_title>
	<detailed_description>The objective study evaluate safety efficacy ophthalmic intravitreal injection ALG - 1001 human subject diabetic macular edema . The primary endpoint study observation dose limit toxicity maximum tolerate dose . The secondary endpoint study observation clinical effect best correct visual acuity ( BCVA ) ( ETDRS letter ) OCT central macular thickness .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<criteria>1 . Male female subject , 18 year age old . 2 . Patient ( male female ) active diabetic macular edema ( DME ) . 3 . Patient whose study eye best correct visual acuity ( BCVA ) 20/50 20/160 ETDRS equivalent ( 65 letter 36 letter ) , opinion investigator primarily due DME intravitreally inject 0.10 cc contain 1.5mg/100µl 2.5mg/100µl ALG1001 . Decrease BCVA must assess base clinical exploration , macular thickening , presence clinical significant macular edema and/or OCT finding consistent diabetic macular edema . 4 . Patient whose study eye best correct visual acuity ( BCVA ) 20/200 bad ETDRS equivalent ( 35 letter less ) , opinion investigator primarily due DME intravitreally inject 0.10 cc contain 5.0mg/100µl 7.5mg/100µl ALG1001 . Decrease BCVA must assess base clinical exploration , macular thickening , presence clinical significant macular edema and/or OCT finding consistent diabetic macular edema . 5 . Patients IntraOcular Pressure ( IOP ) control , IOP ≤ 25 mm 6 . Patient willing able return study visit . 7 . Patient able meet extensive postop evaluation regimen 8 . Patient understand sign Informed Consent form . 1 . Patients Media Opacities abnormality would preclude observation Retina . 2 . Patients active Proliferative Diabetic Retinopathy ( PDR ) study eye NVE , NVD , Vitreous Hemorrhage , Neovascular Glaucoma . 3 . Patients current prior Retinal Detachments , Retinal tear , Tractional Detachments either eye . 4 . Patients significant epiretinal membrane determine investigator contribute macular edema . 5 . Patients retinal pathology would interfere vision . 6 . Patient Chronic Recurrent Uveitis . 7 . Patient undergone Vitrectomy ( anterior par plana ) study eye . 8 . Patient ongoing Ocular infection inflammation either eye . 9 . Patient history intravitreal injection type study eye within last 45 day prior study enrollment . 10 . Patient history focal laser type study eye within last 90 day prior study enrollment . 11 . Patient history cataract surgery complications/vitreous loss study eye . 12 . Patient congenital eye malformation study eye . 13 . Patient history penetrate Ocular Trauma study eye . 14 . Patient mentally handicap . 15 . Patient Pregnant Nursing female . If subject 18 60 year old . Negative pregnancy test screening window . 16 . Patient currently participate Clinical Research Study 17 . Patient contraindication study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Diabetic Macular Edema</keyword>
</DOC>